Related Experiment Video

Updated: Aug 10, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[Current aspects of drug treatment of patients with congestive heart failure]

O Bertel

    Schweizerische Medizinische Wochenschrift
    |May 21, 1983
    PubMed

    Insights

    Effective congestive heart failure treatment prioritizes unburdening the heart with diuretics and vasodilators. Digoxin is key for arrhythmias and as add-on therapy in heart failure management.

    Area of Science:

    • Cardiology
    • Pharmacology

    Context:

    • Advanced congestive heart failure (CHF) presents significant patient morbidity, high healthcare costs, and poor prognosis.
    • Current treatment paradigms for CHF are often traditional rather than evidence-based on pathophysiology.
    • Optimizing medical care for CHF patients requires a shift towards pathophysiologically informed strategies.

    Purpose:

    • To outline a rational, pathophysiology-driven treatment approach for advanced congestive heart failure.
    • To emphasize the principle of "unburdening" the failing heart over cardiac stimulation.
    • To provide guidelines for a stepwise therapeutic regimen.

    Summary:

    • A pathophysiology-based approach to advanced congestive heart failure (CHF) management is proposed.
    • Prioritizing cardiac "unburdening" through diuretics and vasodilators is crucial, particularly in hypertensive heart disease, valvular incompetence, and acute heart failure.
    • Digoxin remains foundational for tachyarrhythmias and beneficial as adjunctive therapy in most CHF cases.

    Impact:

    • This approach aims to improve outcomes for patients with advanced congestive heart failure.
    • Implementing a stepwise treatment scheme incorporating diuretics, vasodilators, and digoxin can optimize CHF management.
    • Shifting from traditional to pathophysiological treatment principles may enhance the effectiveness of CHF therapy.

    More Related Videos

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

    Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

    Published on: August 2, 2024

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.